Canaccord analyst John Newman lowered the firm’s price target on Oncolytics to $5.00 from $6.00 and keeps a Buy rating on the shares. The analyst said we look forward to BRACELET-1 data in 2Q23 and more information on the future registrational study pathway for breast cancer and PDAC. Additionally, we look forward to GOBLET trial updates in PDAC, CRC, and anal cancer in 2H23.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ONCY:
- Oncolytics initiated with an Overweight at Cantor Fitzgerald
- Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
- Oncolytics reports Q4 EPS (C$0.14) vs. (C$0.14) last year
- Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
